Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP Images)
Pfizer says RSV shot to protect infants may be available by 2023-24 cold and flu season
Pfizer’s vaccine to protect infants from RSV may be approved before the next cold and flu season, the company said on Tuesday.
Regulators granted RSVpreF, also known as PF-06928316, a priority review for the prevention of medically attended lower respiratory tract illness (MA-LRTI) caused by RSV in infants. The shot would be administered during pregnancy to protect infants from birth to 6 months old.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters